WEC
CBAY

Winslow Evans & Crocker’s Cymabay Therapeutics CBAY Stock Holding History

Winslow Evans & Crocker’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-80
Closed -$2K – 1371
2019
Q1 		$2K Hold
80
– – ﹤0.01% 1286
2018
Q4 		$2K Hold
80
– – ﹤0.01% 1070
2018
Q3 		$2K Hold
80
– – ﹤0.01% 1081
2018
Q2 		$2K Buy
+80
New +$1K ﹤0.01% 1092

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Winslow Evans & Crocker's CBAY Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 80 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in CBAY in Q2 2018 and held it in 4 quarters. The position peaked at $2K in Q1 2019. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

  • Winslow Evans & Crocker reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Winslow Evans & Crocker sold 80 Cymabay Therapeutics shares in Q2 2019, an estimated $2K.
  • Winslow Evans & Crocker first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 4 quarters.
  • Winslow Evans & Crocker's Cymabay Therapeutics position peaked at $2K in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.